GT Biopharma Advances Three TriKE Candidates, Initiates GTB-5550 Prostate Cancer Trial
ARTV•GT Biopharma’s clinical-stage TriKE platform has three drug candidates dosing in Phase 1 trials, including lead program GTB-3650 for AML/MDS with Cohort 4 enrollment complete and no dose-limiting toxicities. In May 2026 the company initiated dosing of GTB-5550 targeting B7-H3 in metastatic prostate cancer and plans a broad solid-tumor basket study.
1. Small Market Cap, Exclusive Platform
GT Biopharma’s market capitalization stood at roughly $13 million as of mid-May 2026 despite holding an exclusive license to the Tri-specific Killer Engager platform from the University of Minnesota, which drives three separate immuno-oncology candidates into human trials.
2. GTB-3650 Phase 1 Trial Milestones
The lead TriKE candidate, GTB-3650 for relapsed/refractory CD33-positive AML and high-risk MDS, has completed Cohort 4 enrollment with eight patients and no dose-limiting toxicities, paving the way for escalation through up to seven dose cohorts and a planned data update in the second half of 2026.
3. GTB-5550 Launches Solid Tumor Program
In May 2026 the company dosed the first patient in the Phase 1 trial of GTB-5550 targeting B7-H3, beginning in prostate cancer and set to expand into a basket trial across up to seven solid tumor types using subcutaneous dosing for improved patient convenience.
4. Vast Oncology Market Opportunity
The global oncology market is projected to grow from $139 billion in 2025 to $268 billion by 2034, with solid tumors alone representing hundreds of billions in potential revenue and B7-H3 expression in over 90% of metastatic prostate cancers highlighting the platform’s commercial upside.
